Evaluation criteria for vaccines for endemic disease prevention through routine immunisation

in page functions
[French]
 

Criteria

Indicators

Ranking criteria:

Health impact

Total future deaths averted in the 2020-2035 period, and per 100,000 vaccinated
Total future cases averted in the 2020-2035 period, and per 100,000 vaccinated

Value for money

Vaccine procurement cost per death averted
Vaccine procurement cost per case averted

Equity and social protection impact

Disproportionate impact of disease on vulnerable groups
Special benefits of vaccination for women and girls

Economic impact

Direct medical costs averted
Indirect costs averted

Global health security impact

Epidemic potential of disease
Impact of vaccination on antimicrobial resistance (AMR)

Secondary criteria:

Other impact

Total under-five deaths averted in the 2020-2035 period, and per 100,000 vaccinated
Total DALYs averted in the 2020-2035 period, and per 100,000 vaccinated
Vaccine procurement cost per disability-adjusted life year (DALY) averted

Gavi comparative advantage

Degree of vaccine market challenges
Potential for Gavi support to catalyse additional investment

Implementation feasibility

Ease of supply chain integration
Need for healthcare worker behaviour change
Feasibility of vaccination time point
Acceptability in target population
Long-term financial implications

Alternative interventions

Optimal use of current and future alternative interventions (prevention and treatment)

Broader health system benefits

No specific indicator – evaluated on a case-by-case basis 

Financial implications:

Vaccine cost

Total procurement cost to Gavi and countries, 2020-2035

Operational cost

Incremental in-country operational costs per vaccinated person

Additional implementation costs

Additional costs for introduction

 

close icon

modal window here